Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

A potent and selective catalytic inhibitor of p300/CBP histone acetyltransferases suppresses tumour proliferation across multiple cell lineages, illustrating the therapeutic potential of drug-like small molecules that target histone acetyltransferases.